Patient characteristics
| . | Treatment arm . | |
|---|---|---|
| Observation (n=122), n (%) . | Rituximab maintenance (n=99), n (%) . | |
| Age >60 y | 42 (34) | 34 (34) |
| Age, y | 56 (23-80) | 54 (28-76) |
| Male sex | 58 (48) | 51 (52) |
| FLIPI score | ||
| Low (0-1 risk factors) | 27 (22) | 20 (20) |
| Intermediate (2 risk factors) | 43 (35) | 39 (39) |
| High (3-5 risk factors) | 52 (43) | 40 (40) |
| Induction regimen | ||
| R-CHOP | 114 (93) | 95 (96) |
| R-CVP | 8 (7) | 4 (4) |
| R-FCM | 0 (0) | 0 (0) |
| Response to induction | ||
| Complete response | 89 (73) | 75 (76) |
| Partial response | 33 (27) | 24 (24) |
| Other | 0 (0) | 0 (0) |
| . | Treatment arm . | |
|---|---|---|
| Observation (n=122), n (%) . | Rituximab maintenance (n=99), n (%) . | |
| Age >60 y | 42 (34) | 34 (34) |
| Age, y | 56 (23-80) | 54 (28-76) |
| Male sex | 58 (48) | 51 (52) |
| FLIPI score | ||
| Low (0-1 risk factors) | 27 (22) | 20 (20) |
| Intermediate (2 risk factors) | 43 (35) | 39 (39) |
| High (3-5 risk factors) | 52 (43) | 40 (40) |
| Induction regimen | ||
| R-CHOP | 114 (93) | 95 (96) |
| R-CVP | 8 (7) | 4 (4) |
| R-FCM | 0 (0) | 0 (0) |
| Response to induction | ||
| Complete response | 89 (73) | 75 (76) |
| Partial response | 33 (27) | 24 (24) |
| Other | 0 (0) | 0 (0) |